中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

55 records (took 0.025 seconds)

    AUDIO INFORMATION INCORPORATED WITHIN MRI PULSE SEQUENCES
    1.
    发明申请
    AUDIO INFORMATION INCORPORATED WITHIN MRI PULSE SEQUENCES 审中-公开
    与MRI脉冲序列相关的音频信息

    公开(公告)号：WO1997034527A1

    公开(公告)日：1997-09-25

    申请号：PCT/US1997004388

    申请日：1997-03-19

    Applicant: CASE WESTERN RESERVE UNIVERSITY

    Inventor： CASE WESTERN RESERVE UNIVERSITY ,  DUERK, Jeffrey, L. ,  NAIR, Meera, S. ,  WU, Dee, Hung ,  LEWIN, Jonathan, S.

    IPC: A61B05/05

    CPC classification number: G01R33/283

    Abstract: Audio information is spoken into a microphone and saved in digitized form in an electronic file (40). The digitized information is converted into a format which is usable within a particular MRI system (42). Thereafter, an electronically store pulse sequence, useable within the selected MRI system, is selected (46) and edited (48) to incorporate the converted digitized verbal information (50) and appropriate header information (44). When the edited pulse sequence is operated by the MRI system, audio information is projected which can be heard by the human ear using the elements of an existing MRI system.

    Abstract translation: 音频信息被传送到麦克风中并以数字化形式保存在电子文件中（40）。 数字化信息被转换为可在特定MRI系统（42）内使用的格式。 此后，选择（46）并编辑（48）所选择的MRI系统内可用的电子存储脉冲序列以合并转换的数字化语言信息（50）和适当的标题信息（44）。 当编辑的脉冲序列由MRI系统操作时，投影可以使用现有MRI系统的元件由人耳听到的音频信息。

    A NOVEL DISINTEGRIN METALLOPROTEASE AND METHODS OF USE
    2.
    发明申请
    A NOVEL DISINTEGRIN METALLOPROTEASE AND METHODS OF USE 审中-公开
    一种新型消毒金属蛋白酶及其使用方法

    公开(公告)号：WO1997031931A1

    公开(公告)日：1997-09-04

    申请号：PCT/US1997003217

    申请日：1997-02-28

    Applicant: THE PROCTER & GAMBLE COMPANY ,  CASE WESTERN RESERVE UNIVERSITY ,  TINDAL, Michael, Howard ,  HAQQI, Tariq

    Inventor： THE PROCTER & GAMBLE COMPANY ,  CASE WESTERN RESERVE UNIVERSITY

    IPC: C07H21/02

    CPC classification number: C12N9/6489 ,  A61K38/00 ,  G01N33/573 ,  G01N2333/96486 ,  Y02A50/401

    Abstract: This invention provides a method for identifying compounds capable of binding to the disintegrin protein, and determining the amount and affinity of a compound capable of binding to the disintegrin protein in a sample. This invention also provides a host cell comprising a recombinant expression vector to the disintegrin protein and a recombinant expression vector encoding to the disintegrin protein and the human disintegrin metalloprotease protein, fragment or mutant thereof, useful for these purposes. This invention also provides an in vivo or in vitro method for screening for osteoarthritis and other metalloprotease based diseases, capable of manufacture and use in a kit form.

    Abstract translation: 本发明提供了一种鉴定能够结合去整合素蛋白质的化合物的方法，以及测定能够结合样品中的去整合素蛋白质的化合物的量和亲和力。 本发明还提供了一种宿主细胞，其包含重组表达载体至去整合素蛋白质，以及重组表达载体，其编码可用于这些目的的去整合素蛋白质和人解嵌入金属蛋白酶蛋白质，其片段或突变体。 本发明还提供了用于筛选能够以试剂盒形式制造和使用的骨关节炎和其它基于金属蛋白酶的疾病的体内或体外方法。

    NEURONAL CHOLINERGIC DIFFERENTIATION FACTOR
    6.
    发明申请
    NEURONAL CHOLINERGIC DIFFERENTIATION FACTOR 审中-公开
    神经精神分裂症因子

    公开(公告)号：WO1992011026A1

    公开(公告)日：1992-07-09

    申请号：PCT/US1991009650

    申请日：1991-12-19

    Applicant: CASE WESTERN RESERVE UNIVERSITY

    Inventor： CASE WESTERN RESERVE UNIVERSITY ,  RAO, Mahendra, S. ,  LANDIS, Story, C.

    IPC: A61K37/66

    CPC classification number: C07K16/18 ,  C07K14/475

    Abstract: The present invention is directed to a target-derived neuronal cholinergic differenciation factor (NCDF), and the therapeutic and diagnostic uses thereof. The invention provides NCDF, and derivatives, analogs, and fragments thereof, pharmaceutical compositions containing the foregoing, as well as anti-NCDF antibodies. The NCDF of the invention is a protein present in extracts of mammalian sweat glands, which exhibits heat and trypsin lability, lack of substantial binding to a heparin-agarose affinity column, an isoelectric point (pI) in the range of approximately 4.8 to 5.2, a non-membrane cellular localization, and an approximate molecular weight in the range of 16 to 32 kilodaltons. The NCDF protein, its derivatives, analogs, and fragments are able to reduce the expression of tyrosine hydroxylase and of total catecholamines, and increase the expression of choline acetyltransferase and vasoactive intestinal peptide (VIP), by sympathetic neurons in cell culture. The NCDF protein, its derivatives, analogs, and fragments, can be used to induce cholinergic activity in neurons. Such proteins, derivatives, analogs and fragments can be administered therapeutically to patients with nervous system damage or diseases where it is desirable to support survival and/or cholinergic differentiation of a number of neuronal types.

    Abstract translation: 本发明涉及靶向神经元胆碱能差异因子（NCDF）及其治疗和诊断用途。 本发明提供NCDF及其衍生物，类似物和片段，含有前述物质的药物组合物以及抗NCDF抗体。 本发明的NCDF是存在于哺乳动物汗腺的提取物中的蛋白质，其表现出热和胰蛋白酶不稳定性，缺乏与肝素 - 琼脂糖亲和柱的实质性结合，等电点（pI）在约4.8至5.2的范围内， 非膜细胞定位，以及16至32千道尔顿范围内的近似分子量。 NCDF蛋白，其衍生物，类似物和片段能够减少酪氨酸羟化酶和总儿茶酚胺的表达，并通过细胞培养中的交感神经元增加胆碱乙酰转移酶和血管活性肠肽（VIP）的表达。 NCDF蛋白，其衍生物，类似物和片段可用于诱导神经元中的胆碱能活性。 这些蛋白质，衍生物，类似物和片段可以治疗性地给患有神经系统损伤或疾病的患者施用，其中需要支持许多神经元类型的存活和/或胆碱能分化。

    PROCESS FOR CONTROLLING CELL GROWTH ON SURFACES
    7.
    发明申请
    PROCESS FOR CONTROLLING CELL GROWTH ON SURFACES 审中-公开
    控制表面细胞生长的方法

    公开(公告)号：WO1992000047A1

    公开(公告)日：1992-01-09

    申请号：PCT/US1991004466

    申请日：1991-06-20

    Applicant: CASE WESTERN RESERVE UNIVERSITY

    Inventor： CASE WESTERN RESERVE UNIVERSITY ,  SUKENIKK, Chaim, N. ,  CULP, Lloyd, A.

    IPC: A61F02/54

    CPC classification number: B82Y30/00 ,  A61L27/34 ,  A61L27/38 ,  C12N5/0068 ,  C12N2533/52 ,  A61L27/06 ,  C08L89/00

    Abstract: A process for selecting the types of cells that will grow on a structure, such as an implantable device or a cell growth surface. The implantable device may have a titanium surface. The process includes attaching a molecular monolayer to the surface of the structure. The monolayer has a functional group at its distal end. The possible function groups include CH3, CH=CH2, Br, CN, COOH, and CHOHCH2OH. The monolayer is coated with an adhesion-mediating molecule such as fibronectin. Cells then contact the coating. The character of the functional group affects the growth characteristics of the adhering or contacting cell, independently of the nature of the underlying structure. Also disclosed is a method of preparing a metallic surface such as titanium to receive a molecular monolayer. The surface is placed in hot water (40-50 DEG C) for 4 hours with sonication, or in boiling water for 8 hours without sonication.

    Abstract translation: 用于选择将在诸如可植入装置或细胞生长表面的结构上生长的细胞类型的方法。 可植入装置可具有钛表面。 该方法包括将分子单层连接到结构的表面。 单层在其远端具有官能团。 可能的官能团包括CH 3，CH = CH 2，Br，CN，COOH和CHOHCH 2 OH。 单层涂有粘附介导分子如纤连蛋白。 然后细胞接触涂层。 官能团的特征独立于底层结构的性质影响粘附或接触电池的生长特性。 还公开了制备诸如钛的金属表面以接收分子单层的方法。 将表面放置在热水（40-50℃）中超声处理4小时，或在沸水中放置8小时而不进行超声处理。

    INHIBITION OF CELL GROWTH BY KERATAN SULFATE, CHONDROITIN SULFATE, DERMATAN SULFATE AND OTHER GLYCANS
    8.
    发明申请
    INHIBITION OF CELL GROWTH BY KERATAN SULFATE, CHONDROITIN SULFATE, DERMATAN SULFATE AND OTHER GLYCANS 审中-公开
    通过硫酸钙，硫酸锌，硫酸铝和其他甘油的细胞生长抑制

    公开(公告)号：WO1991006303A1

    公开(公告)日：1991-05-16

    申请号：PCT/US1990006189

    申请日：1990-10-26

    Applicant: CASE WESTERN RESERVE UNIVERSITY ,  GLIATECH, INC.

    Inventor： CASE WESTERN RESERVE UNIVERSITY ,  GLIATECH, INC. ,  SNOW, Diane, M. ,  SILVER, Jerry ,  HAREL, Adrian ,  ROUFA, Dikla

    IPC: A61K31/715

    CPC classification number: A61K31/715 ,  A61K31/70 ,  C07K16/18 ,  C12N9/2408 ,  Y02A50/472 ,  A61K2300/00

    Abstract: The present invention is directed to methods of using keratan sulfate, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, and hyaluronic acid, and molecules and compositions comprising keratan sulfate, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, and hyaluronic acid, to inhibit or prevent neurite outgrowth, i.e., axonal growth, or nerve regeneration (colectively termed herein ''nerve growth''), or glial cell migration or invasion, or regeneration, and therapeutically, where the foregoing is desired. In another embodiment of the invention, inhibitors and antagonists of keratan sulfate, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, and hyaluronic acid, and molecules and compositions containing the same, may be used to promote nerve growth or glial cell migration or invasion, and can be administered therapeutically. Such inhibitors and antagonists include but are not limited to antibodies, degradative enzymes, lectins; and disaccharide antagonists of the receptors for keratan sulfate, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin or hyaluronate.

    Abstract translation: 本发明涉及使用硫酸角质素，硫酸软骨素，硫酸皮肤素，硫酸乙酰肝素，肝素和透明质酸的方法，以及包含硫酸角质素，硫酸软骨素，硫酸皮肤素，硫酸乙酰肝素，肝素和透明质酸的分子和组合物， 抑制或预防神经突生长，即轴突生长或神经再生（本文称为“神经生长”）或神经胶质细胞迁移或侵袭或再生，并且在治疗上需要上述内容。 在本发明的另一个实施方案中，可以使用硫酸角质素，硫酸软骨素，硫酸皮肤素，硫酸乙酰肝素，肝素和透明质酸的抑制剂和拮抗剂，以及包含其的分子和组合物来促进神经生长或神经胶质细胞迁移或侵袭 ，并且可以治疗地施用。 这些抑制剂和拮抗剂包括但不限于抗体，降解酶，凝集素; 以及硫酸角质素，硫酸软骨素，硫酸皮肤素，硫酸乙酰肝素，肝素或透明质酸的受体的二糖拮抗剂。

    PROCESS FOR DETECTING PENTOSIDINE AND FOR ASSESSING THE BIOLOGICAL AGE OF A BIOLOGICAL SAMPLE
    10.
    发明申请
    PROCESS FOR DETECTING PENTOSIDINE AND FOR ASSESSING THE BIOLOGICAL AGE OF A BIOLOGICAL SAMPLE 审中-公开
    用于检测庞替胺和评估生物样品生物学年龄的方法

    公开(公告)号：WO1997007803A1

    公开(公告)日：1997-03-06

    申请号：PCT/US1996013952

    申请日：1996-08-23

    Applicant: CASE WESTERN RESERVE UNIVERSITY ,  MONNIER, Vincent, M. ,  SELL, David, R.

    Inventor： CASE WESTERN RESERVE UNIVERSITY

    IPC: A61K31/52

    CPC classification number: C07D471/04 ,  G01N33/5308

    Abstract: The present invention is directed to a novel imidazo [4,5b] pyridinium molecule composed of a lysine and an arginine residue crosslinked with a pentose sugar. The novel imidazo [4,5b] pyridinium compound, referred to as "pentosidine", was isolated from proteineous tissue undergoing advanced glycosylation and is believed to be one of the principal products involved in the aging of proteins. Assaying for the pentosidine molecule makes it possible to assess the degree of non-enzymatic glycosylation occurring. In addition, the pentosidine molecule is utilized through the production of antibodies thereto and/or the preparation of test kits, etc., for diagnostic, as well as therapeutic purposes (i.e. development of agents which inhibit the non-enzymatic browning reaction, etc.). For example, the invention further relates to a process for assessing aging in mammals by quantitating the amount of pentosidine present in tissue produced by glycoxidation.

    Abstract translation: 本发明涉及一种由赖氨酸和与戊糖交联的精氨酸残基组成的新型咪唑并[4,5b]吡啶鎓分子。 被称为“戊糖苷”的新型咪唑并[4,5b]吡啶鎓化合物从经历高级糖基化的蛋白质组织中分离出来，被认为是参与蛋白质老化的主要产物之一。 测定戊糖苷分子使得可以评估发生的非酶糖基化程度。 此外，戊糖苷分子通过生产其抗体和/或用于诊断和治疗目的（即抑制非酶促褐变反应的试剂的开发等）的试剂盒等的制备被利用。 ）。 例如，本发明进一步涉及通过定量由糖氧化产生的组织中存在的戊糖苷的量来评估哺乳动物的老化的方法。

Patent Agency Ranking